Warner Chilcott and Barr settle Femcon dispute

Warner Chilcott and Barr Laboratories have entered into a settlement and license agreement to resolve the pending patent litigation involving the  former's oral contraceptive product, Femcon Fe (norethindrone and  ethinyl estradiol ), chewable and ferrous fumarate tablets).

Under the terms of the , Barr will have a license to launch a generic  version of Femcon Fe as early as July 1, 2012, around seven years before  the expiration of the Warner Chilcott patent at issue in the  litigation, or earlier in certain circumstances. Barr will pay Warner  Chilcott a royalty on its net sales of the generic product. The parties  will promptly file a dismissal without prejudice in the US District  Court for the District of New Jersey that will conclude this litigation.